GlassScriptPhysician profile
Patricia Choy
NPI 1477545168
$3,236.96
in general payments reported to CMS, 2019-2025
32 companies · $664 in 2025
The $664 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $234 · 2021: $214 · 2022: $457 · 2023: $668 · 2024: $640 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.91 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $424.75 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $381.36 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $310.64 | 2019-2023 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $289.55 | 2019-2025 | |
| Hologic Sales and Service, LLC | $251.31 | 2019-2025 | Thinprep 2000 Processor, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Mayne Pharma Commercial LLC | $223.12 | 2021-2025 | |
| Myovant Sciences INC. | $154.73 | 2021-2022 | |
| Biogen, INC. | $136.74 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $133.09 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Agile Therapeutics, INC. | $104.83 | 2022-2024 | Twirla |
| Evofem Biosciences, INC. | $96.55 | 2023-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $69.33 | 2022-2025 | Nexplanon |
| Amag Pharmaceuticals, INC. | $65.63 | 2019-2020 | |
| Millicent US INC | $64.83 | 2023-2024 | Femring, Intrarosa |
| Smith+Nephew, INC. | $48.78 | 2024 | Stravix Pl |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $47.75 | 2025 | Perclot |
| Exeltis, USA INC. | $46.97 | 2024-2025 | Slynd |
| Myriad Women'S Health, INC. | $44.20 | 2023 | Myrisk |
| Mylan Pharmaceuticals INC. | $43.41 | 2021-2022 | |
| Daiichi Sankyo INC. | $38.74 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $31.75 | 2021-2022 | |
| Lupin INC. | $29.55 | 2019-2020 | |
| Allergan, INC. | $27.14 | 2019 | |
| Therapeuticsmd, INC. | $24.89 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $24.02 | 2019 | |
| Medtronic, INC. | $23.25 | 2025 | Truclear |
| Pacira Pharmaceuticals Incorporated | $22.81 | 2021 | |
| Medicem INC. | $16.97 | 2021 | |
| Pfizer INC. | $15.80 | 2024 | |
| Optumhealth Care Solutions, LLC | $15.42 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Novo Nordisk INC | $15.12 | 2023 | Wegovy |
| Covidien LP | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Choy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.